The large-scale facility, to be built in Visp, Switzerland, will be established through a joint venture with an initial investment of around CHF 290 million (€270 million) shared equally between Sanofi and Lonza
The strategic partnership leverages Lonza’s expertise in large-scale mammalian cell culture facilities alongside Sanofi’s strength in developing and launching biologics based treatments to address patient needs. Lonza will construct the facility and will support the joint venture in its operation of the facility.
The initial phase of the facility will commence construction in 2017, pending necessary regulatory approvals, and is expected to be fully operational by 2020. Lonza has previously built and licensed three similar facilities in the US and Singapore.
Marc Funk is COO Pharma & Biotech at Lonza. He said: “We intend to address long-term market needs by establishing a state-of-the-art strategic biologics manufacturing platform.
“Approximately 60% of our pipeline is made up of biologics, including monoclonal antibodies, dedicated to key disease areas such as cardiovascular, immunology and inflammation, neurology and oncology,” said Philippe Luscan, Executive Vice President, Global Industrial Affairs at Sanofi.
“Lonza is a highly experienced partner in this field and the capabilities this joint venture will create are critical to meeting our patients’ needs for these important therapies.”
The partnership provides both Sanofi and Lonza with substantial flexibility:
The strategic partnership enables Sanofi to react quickly to fluctuations in demand in a short timeframe, reinforcing their capability to launch high-quality, next generation biologic medicines and ensure consistent access for patients.
It also provides Lonza with the capacity to respond to growing manufacturing demands for large-scale mammalian cell culture based therapeutic proteins. By adding flexibility in this way, it is hoped this model will optimise biologics production capacity across the whole industry.
Source: Manufacturing Chemist
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
